AVROBIO, Inc. (NASDAQ:AVRO) Short Interest Update

AVROBIO, Inc. (NASDAQ:AVROGet Free Report) saw a large decrease in short interest in the month of August. As of August 31st, there was short interest totalling 1,770,000 shares, a decrease of 18.4% from the August 15th total of 2,170,000 shares. Currently, 4.6% of the shares of the stock are short sold. Based on an average trading volume of 1,160,000 shares, the short-interest ratio is currently 1.5 days.

Wall Street Analyst Weigh In

A number of research analysts have issued reports on the company. Wells Fargo & Company decreased their target price on AVROBIO from $2.50 to $2.00 in a research report on Thursday, July 13th. Wedbush downgraded AVROBIO from an “outperform” rating to a “neutral” rating in a research report on Wednesday, July 12th.

View Our Latest Report on AVRO

Institutional Trading of AVROBIO

A number of institutional investors have recently bought and sold shares of the company. BlackRock Inc. lifted its stake in shares of AVROBIO by 9.6% in the 1st quarter. BlackRock Inc. now owns 3,788,727 shares of the company’s stock valued at $5,000,000 after purchasing an additional 332,639 shares during the period. Renaissance Technologies LLC raised its holdings in shares of AVROBIO by 175.7% in the 1st quarter. Renaissance Technologies LLC now owns 885,100 shares of the company’s stock worth $1,168,000 after acquiring an additional 564,100 shares during the last quarter. Mirabella Financial Services LLP bought a new position in AVROBIO in the 1st quarter valued at about $42,000. Walleye Capital LLC increased its holdings in AVROBIO by 37.0% during the 1st quarter. Walleye Capital LLC now owns 198,926 shares of the company’s stock worth $263,000 after purchasing an additional 53,767 shares in the last quarter. Finally, JPMorgan Chase & Co. lifted its holdings in shares of AVROBIO by 6.3% in the second quarter. JPMorgan Chase & Co. now owns 2,120,044 shares of the company’s stock valued at $1,950,000 after purchasing an additional 125,653 shares in the last quarter. Institutional investors own 59.95% of the company’s stock.

AVROBIO Trading Down 0.3 %

Shares of AVRO stock traded down $0.01 on Monday, hitting $1.56. The company had a trading volume of 118,722 shares, compared to its average volume of 1,624,344. The stock’s 50-day moving average is $1.50 and its two-hundred day moving average is $1.18. AVROBIO has a twelve month low of $0.56 and a twelve month high of $1.93.

AVROBIO (NASDAQ:AVROGet Free Report) last issued its quarterly earnings results on Thursday, August 10th. The company reported ($0.37) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.35 by ($1.72). On average, equities research analysts forecast that AVROBIO will post 0.65 earnings per share for the current year.


(Get Free Report)

AVROBIO, Inc, a clinical-stage gene therapy company, develops ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose worldwide. Its gene therapies employ hematopoietic stem cells that are harvested from the patient and then modified with a lentiviral vector to insert the equivalent of a functional copy of the gene that is mutated in the target disease.

Recommended Stories

Receive News & Ratings for AVROBIO Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AVROBIO and related companies with MarketBeat.com's FREE daily email newsletter.